Beyond Mineral Metabolism, is There an Interplay Between FGF23 and Vitamin D in Innate Immunity?

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2012 Nov 3

PMID 23117582

Citations 17

Authors

Justine Bacchetta

Isidro B Salusky

Martin Hewison

Affiliations

Soon will be listed here.

Abstract

Fibroblast growth factor 23 (FGF23) is an "endocrine" FGF acting in the kidney as a phosphaturic hormone and a suppressor of active vitamin D, through an inhibition of the 1α hydroxylase and a stimulation of the 24 hydroxylase. Beyond its well-known effects on the bone/kidney/parathyroid axis and its deregulation during chronic kidney disease (CKD), recent evidence has revealed its direct systemic effects on cardiovascular health. In the meantime, studies have highlighted the health implications for vitamin D inside and outside CKD that also extend beyond its classical actions on mineral homeostasis and bone metabolism: vitamin D has indeed been shown to exert pluripotent non-classical effects as a modulator of immune function in monocytes, mainly through the stimulation of the antimicrobial cathelicidin. The aim of this review is to provide new insights on the interplay between FGF23 and vitamin D in innate immunity in the context of CKD.

Citing Articles

Associations of Intact and C-Terminal FGF23 with Inflammatory Markers in Older Patients Affected by Advanced Chronic Kidney Disease.

Abinti M, Vettoretti S, Caldiroli L, Mattinzoli D, Ikehata M, Armelloni S J Clin Med. 2024; 13(13).

PMID: 38999530 PMC: 11242756. DOI: 10.3390/jcm13133967.

Fibroblast growth factor 23 during septic shock and myocardial injury in ICU patients.

Yang Z, Wang J, Ma J, Ren D, Li Z, Fang K Heliyon. 2024; 10(6):e27939.

PMID: 38509994 PMC: 10950713. DOI: 10.1016/j.heliyon.2024.e27939.

COVID-19 Vaccination in Kidney Transplant Candidates and Recipients.

Ponticelli C, Campise M Vaccines (Basel). 2022; 10(11).

PMID: 36366317 PMC: 9692413. DOI: 10.3390/vaccines10111808.

The Role of Vitamin D in SARS-CoV-2 Infection and Acute Kidney Injury.

Hsieh M, Hsiao P, Liao M, Hou Y, Chang Y, Chiang W Int J Mol Sci. 2022; 23(13).

PMID: 35806377 PMC: 9266309. DOI: 10.3390/ijms23137368.

Association of FGF23 with Incident Sepsis in Community-Dwelling Adults: A Cohort Study.

Paul S, Judd S, Wang H, Gutierrez O Kidney360. 2022; 1(9):950-956.

PMID: 35369560 PMC: 8815598. DOI: 10.34067/KID.0000942020.

References

Klaus G, Watson A, Edefonti A, Fischbach M, Ronnholm K, Schaefer F . Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol. 2005; 21(2):151-9. PMC: 1766475. DOI: 10.1007/s00467-005-2082-7. View

Srivaths P, Goldstein S, Silverstein D, Krishnamurthy R, Brewer E . Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011; 26(6):945-51. DOI: 10.1007/s00467-011-1822-0. View

Gombart A, Bhan I, Borregaard N, Tamez H, Camargo Jr C, Koeffler H . Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin Infect Dis. 2009; 48(4):418-24. PMC: 6944311. DOI: 10.1086/596314. View

Hiep T, Ismaili K, Collart F, van Damme-Lombaerts R, Godefroid N, Ghuysen M . Clinical characteristics and outcomes of children with stage 3-5 chronic kidney disease. Pediatr Nephrol. 2010; 25(5):935-40. DOI: 10.1007/s00467-009-1424-2. View

Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S . Mineralized tissue cells are a principal source of FGF23. Bone. 2007; 40(6):1565-73. DOI: 10.1016/j.bone.2007.01.017. View

Vidal M, Ramana C, Dusso A . Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol. 2002; 22(8):2777-87. PMC: 133712. DOI: 10.1128/MCB.22.8.2777-2787.2002. View

Fukagawa M, Nii-Kono T, Kazama J . Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens. 2005; 14(4):325-9. DOI: 10.1097/01.mnh.0000172717.49476.80. View

Parasuraman R, Samarapungavan D, Venkat K . Updated principles and clinical caveats in the management of infection in renal transplant recipients. Transplant Rev (Orlando). 2010; 24(2):43-51. DOI: 10.1016/j.trre.2009.09.001. View

Lafage-Proust M . Does the downregulation of the FGF23 signaling pathway in hyperplastic parathyroid glands contribute to refractory secondary hyperparathyroidism in CKD patients?. Kidney Int. 2010; 77(5):390-2. DOI: 10.1038/ki.2009.512. View

10.

Adams J, Hewison M . Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab. 2008; 4(2):80-90. PMC: 2678245. DOI: 10.1038/ncpendmet0716. View

11.

Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson K . Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195(1):125-31. DOI: 10.1677/JOE-07-0267. View

12.

Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K . Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2009; 95(2):578-85. PMC: 2840849. DOI: 10.1210/jc.2009-1603. View

13.

Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S . The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010; 95(4):1741-8. DOI: 10.1210/jc.2009-1576. View

14.

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

15.

Juppner H, Wolf M, Salusky I . FGF-23: More than a regulator of renal phosphate handling?. J Bone Miner Res. 2010; 25(10):2091-7. PMC: 3153315. DOI: 10.1002/jbmr.170. View

16.

Chonchol M, Kendrick J, Targher G . Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Ann Med. 2011; 43(4):273-82. PMC: 4030714. DOI: 10.3109/07853890.2010.543923. View

17.

Chun R, Adams J, Hewison M . Back to the future: a new look at 'old' vitamin D. J Endocrinol. 2008; 198(2):261-9. PMC: 2699326. DOI: 10.1677/JOE-08-0170. View

18.

Vogtlander N, Brown A, Valentijn R, Rimmelzwaan G, Osterhaus A . Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients. Vaccine. 2004; 22(17-18):2199-201. DOI: 10.1016/j.vaccine.2003.11.046. View

19.

Ben-Dov I, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-O M, Mohammadi M . The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117(12):4003-8. PMC: 2066196. DOI: 10.1172/JCI32409. View

20.

Dalrymple L, Go A . Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3(5):1487-93. PMC: 4571152. DOI: 10.2215/CJN.01290308. View